Introduction: Metabolic and bariatric surgery (MBS) is a safe and efficacious weight loss treatment for children and adolescents with severe forms of obesity. However, there are limited long-term data on treatment effectiveness of MBS for youth-onset type 2 diabetes (YO-T2D). We examined 10-year weight and T2D outcomes among adolescents undergoing MBS.

Methods: We analyzed longitudinal data from 21 individuals who prior to MBS (67% Roux-en-Y gastric bypass, 33% vertical sleeve gastrectomy [VSG]) were < 19 years of age, had ≥ Class 2 obesity and YO-T2D, and were prospectively enrolled in the multi-center, Teen Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study.

Definitions: T2D remission= no prescribed glucose lowering medication and normoglycemia (HbA1c <5.7%); partial remission= no medications and HbA1c 5.7%-<6.5%; no remission= current glucose lowering prescription and/or HbA1c ≥ 6.5%. A fasting blood glucose of <100 mg/dL was substituted for one missing follow-up HbA1c. Data presented as mean±SD or percentage.

Results: At the time of MBS, the cohort was 76% female, 57% non-Hispanic white, and had a mean age of 16.7±1.2 years, BMI 53.9±9.2 kg/m2, and HbA1c 6.8±2.0%. At 10-years post-MBS, 71% of individuals (15/21) experienced remission of T2D and had a 29±18% BMI reduction. Remission rates were similar between surgical types. Twenty-nine percent (6/21) did not experience T2D remission by 10 years post-MBS, and only experienced 4±14% BMI decrease. Of the six individuals without remission at 10 years post-MBS, 3/6 previously had remission (in the interim data collection periods) and one had partial remission 1-year post-MBS, with a return of T2D-range HbA1c in subsequent years.

Conclusion: T2D resolution occurred in a high proportion of adolescents post-MBS, and was durable to 10-years of follow-up. Further study is needed to better understand outcomes in diverse populations of YO-T2D, underlying mechanisms of remission and reasons for low weight loss/lack of remission.

Disclosure

S. Sisley: Speaker's Bureau; Rhythm Pharmaceuticals, Inc. A.S. Shah: None. K.J. Nadeau: None. M.M. Kelsey: Other Relationship; Rhythm Pharmaceuticals, Inc., Lilly Diabetes. A. Courcoulas: Research Support; Allurion, Eli Lilly and Company. M. Michalsky: Stock/Shareholder; Intuitive Surgical. Other Relationship; Intuitive Surgical. Advisory Panel; Lilly USA, LLC. T.M. Jenkins: None. J.R. Ryder: None. T. Inge: Consultant; Medtronic, Eli Lilly and Company, Brainstorm Therapeutics. Stock/Shareholder; Standard Bariatrics. Consultant; Teleflex.

Funding

National Institutes of Health (UM1DK072493)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.